Replies to post #243297 on Amarin Corp Plc (AMRN)

[Jeffkad]

CBB The Euro rev # certainly adds another de-risking perspective to the AMRN investment thesis. If the numbers HDG suggests for per patient rev are combined with the potential market penetration, don’t see much downside. My problem (and probably many others) will be that I’m already fully loaded in AMRN and will have to dig up new cash if the post patent case big dip opportunity materializes. In any case, the Europe rev potential makes me feel better and will soften the blow if we lose the patent case.